Abstract

Background: This study aimed to investigate the effects of brimonidine on microglia cell morphology by creating a transient retinal ischemia model in rats. Methods: In the right eyes of male Wistar rats (n = 12), a transient retinal ischemia model was created. The rats were divided into three groups: (1) eyes treated with topical brimonidine in the transient retinal ischemia model, (2) shamtreated eyes, and (3) control eyes. Four main phenotypes (ramified, primed, reactive, and amoeboid-phagocytic) of Iba-1 positive microglia cells were examined in the retinal layers. Results: In the transient retinal ischemia model, the number of Iba-1 positive microglia cells was 100.67 ± 7.50 cells in the sham group and 57.67 ± 14.64 cells in the topical brimonidine group. The decrease in the total number of Iba-1 positive microglial cells was statistically significant (p < 0.05). When we compared ramified and primed microglia cells, there was no statistically significant difference between the groups. The number of amoeboidphagocytic microglial cells was 9.5 ± 1.29 cells in the sham treatment group and 2.25 ± 0.50 cells in the topical brimonidine group (p < 0.05). There was a statistically significant decrease in the number of reactive and amoeboid cells. Conclusion: Studies in the central nervous system in rats demonstrated that cell metabolism and functions were changed after acute injury and that microglia transformed from a ramified form to an amoeboid-phagocytic form. In this study, the decrease in the transition of cells from ramified to reactive and amoeboid forms showed us that topical brimonidine treatment could have neuroinflammation suppressor features.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.